IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients
•A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted. The healthcare system in Iran, like...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2021-10, Vol.99, p.107998-107998, Article 107998 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 107998 |
|---|---|
| container_issue | |
| container_start_page | 107998 |
| container_title | International immunopharmacology |
| container_volume | 99 |
| creator | Tabarsi, Payam Hashemian, Seyed Mohammad Reza Bauhofer, Artur Savadkoohi, Ali Amir Ghadimi, Somayeh Haseli, Sara Dastan, Farzaneh |
| description | •A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted.
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50–60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease.
There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted. |
| doi_str_mv | 10.1016/j.intimp.2021.107998 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8299233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921006342</els_id><sourcerecordid>2579781059</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-ea1d10a5dc0ebb7d7c8972462d53c814ca44a1eb78934650cb877495abbb74f33</originalsourceid><addsrcrecordid>eNp9UU1r3DAUNKWlSdP-g1IMvfSirZ4sWVIPheB-LaQEmjZXIcvPGy22tZHshfz7atk0_TgUBJKe5s3TzBTFS6AroFC_3a78NPtxt2KUQS5JrdWj4hSUVAQkFY_zWdSSCFnrk-JZSltKc53D0-Kk4hUIAHladOvNV4JT9O4Gu9KP4zKFzRDaZfBTmVdzeb3-QEC_KxubsEwYPaYy9CWIfNljxOGu9MNQXp1_uyJNuCaM-KlHN2e6nZ09TnN6Xjzp7ZDwxf1-Vvz49PF784VcXH5eN-cXxHENM0ELHVArOkexbWUnndKS8Zp1onIKuLOcW8BWKl3xWlDXKim5FrbNaN5X1Vnx_si7W9oRO5dnRzuYXfSjjXcmWG_-fpn8jdmEvVFMa1YdCN7cE8Rwu2CazeiTw2GwE4YlGSaE0HXNmM7Q1_9At2GJU5aXUVJLBVQcUPyIcjGkFLF_-AxQc4jRbM0xRnOI0RxjzG2v_hTy0PQrt99KMdu59xhNctlqh52P2XvTBf__CT8BFN6vFA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579781059</pqid></control><display><type>article</type><title>IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tabarsi, Payam ; Hashemian, Seyed Mohammad Reza ; Bauhofer, Artur ; Savadkoohi, Ali Amir ; Ghadimi, Somayeh ; Haseli, Sara ; Dastan, Farzaneh</creator><creatorcontrib>Tabarsi, Payam ; Hashemian, Seyed Mohammad Reza ; Bauhofer, Artur ; Savadkoohi, Ali Amir ; Ghadimi, Somayeh ; Haseli, Sara ; Dastan, Farzaneh</creatorcontrib><description>•A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted.
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50–60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease.
There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted.</description><identifier>ISSN: 1567-5769</identifier><identifier>ISSN: 1878-1705</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.107998</identifier><identifier>PMID: 34315117</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Anti-inflammatory agents ; Computed tomography ; Coronaviruses ; COVID-19 ; COVID-19 - therapy ; Cytokine storm ; Cytokines ; Dexamethasone ; Enrichment ; Health services ; Humans ; Hyperinflammation ; IgM-enriched immunoglobulin ; Immunoglobulin M ; Immunoglobulin M - therapeutic use ; Immunoglobulins ; Inflammation ; Intravenous immunoglobulin (IVIG) ; Iran ; Lung - pathology ; Mortality ; Patients ; SARS-CoV-2 ; Sepsis ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases</subject><ispartof>International immunopharmacology, 2021-10, Vol.99, p.107998-107998, Article 107998</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><rights>Copyright Elsevier BV Oct 2021</rights><rights>2021 Published by Elsevier B.V. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-ea1d10a5dc0ebb7d7c8972462d53c814ca44a1eb78934650cb877495abbb74f33</citedby><cites>FETCH-LOGICAL-c491t-ea1d10a5dc0ebb7d7c8972462d53c814ca44a1eb78934650cb877495abbb74f33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1567576921006342$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34315117$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tabarsi, Payam</creatorcontrib><creatorcontrib>Hashemian, Seyed Mohammad Reza</creatorcontrib><creatorcontrib>Bauhofer, Artur</creatorcontrib><creatorcontrib>Savadkoohi, Ali Amir</creatorcontrib><creatorcontrib>Ghadimi, Somayeh</creatorcontrib><creatorcontrib>Haseli, Sara</creatorcontrib><creatorcontrib>Dastan, Farzaneh</creatorcontrib><title>IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted.
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50–60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease.
There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted.</description><subject>Anti-inflammatory agents</subject><subject>Computed tomography</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - therapy</subject><subject>Cytokine storm</subject><subject>Cytokines</subject><subject>Dexamethasone</subject><subject>Enrichment</subject><subject>Health services</subject><subject>Humans</subject><subject>Hyperinflammation</subject><subject>IgM-enriched immunoglobulin</subject><subject>Immunoglobulin M</subject><subject>Immunoglobulin M - therapeutic use</subject><subject>Immunoglobulins</subject><subject>Inflammation</subject><subject>Intravenous immunoglobulin (IVIG)</subject><subject>Iran</subject><subject>Lung - pathology</subject><subject>Mortality</subject><subject>Patients</subject><subject>SARS-CoV-2</subject><subject>Sepsis</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><issn>1567-5769</issn><issn>1878-1705</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1r3DAUNKWlSdP-g1IMvfSirZ4sWVIPheB-LaQEmjZXIcvPGy22tZHshfz7atk0_TgUBJKe5s3TzBTFS6AroFC_3a78NPtxt2KUQS5JrdWj4hSUVAQkFY_zWdSSCFnrk-JZSltKc53D0-Kk4hUIAHladOvNV4JT9O4Gu9KP4zKFzRDaZfBTmVdzeb3-QEC_KxubsEwYPaYy9CWIfNljxOGu9MNQXp1_uyJNuCaM-KlHN2e6nZ09TnN6Xjzp7ZDwxf1-Vvz49PF784VcXH5eN-cXxHENM0ELHVArOkexbWUnndKS8Zp1onIKuLOcW8BWKl3xWlDXKim5FrbNaN5X1Vnx_si7W9oRO5dnRzuYXfSjjXcmWG_-fpn8jdmEvVFMa1YdCN7cE8Rwu2CazeiTw2GwE4YlGSaE0HXNmM7Q1_9At2GJU5aXUVJLBVQcUPyIcjGkFLF_-AxQc4jRbM0xRnOI0RxjzG2v_hTy0PQrt99KMdu59xhNctlqh52P2XvTBf__CT8BFN6vFA</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Tabarsi, Payam</creator><creator>Hashemian, Seyed Mohammad Reza</creator><creator>Bauhofer, Artur</creator><creator>Savadkoohi, Ali Amir</creator><creator>Ghadimi, Somayeh</creator><creator>Haseli, Sara</creator><creator>Dastan, Farzaneh</creator><general>Elsevier B.V</general><general>Elsevier BV</general><general>Published by Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211001</creationdate><title>IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients</title><author>Tabarsi, Payam ; Hashemian, Seyed Mohammad Reza ; Bauhofer, Artur ; Savadkoohi, Ali Amir ; Ghadimi, Somayeh ; Haseli, Sara ; Dastan, Farzaneh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-ea1d10a5dc0ebb7d7c8972462d53c814ca44a1eb78934650cb877495abbb74f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-inflammatory agents</topic><topic>Computed tomography</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - therapy</topic><topic>Cytokine storm</topic><topic>Cytokines</topic><topic>Dexamethasone</topic><topic>Enrichment</topic><topic>Health services</topic><topic>Humans</topic><topic>Hyperinflammation</topic><topic>IgM-enriched immunoglobulin</topic><topic>Immunoglobulin M</topic><topic>Immunoglobulin M - therapeutic use</topic><topic>Immunoglobulins</topic><topic>Inflammation</topic><topic>Intravenous immunoglobulin (IVIG)</topic><topic>Iran</topic><topic>Lung - pathology</topic><topic>Mortality</topic><topic>Patients</topic><topic>SARS-CoV-2</topic><topic>Sepsis</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tabarsi, Payam</creatorcontrib><creatorcontrib>Hashemian, Seyed Mohammad Reza</creatorcontrib><creatorcontrib>Bauhofer, Artur</creatorcontrib><creatorcontrib>Savadkoohi, Ali Amir</creatorcontrib><creatorcontrib>Ghadimi, Somayeh</creatorcontrib><creatorcontrib>Haseli, Sara</creatorcontrib><creatorcontrib>Dastan, Farzaneh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tabarsi, Payam</au><au>Hashemian, Seyed Mohammad Reza</au><au>Bauhofer, Artur</au><au>Savadkoohi, Ali Amir</au><au>Ghadimi, Somayeh</au><au>Haseli, Sara</au><au>Dastan, Farzaneh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-10-01</date><risdate>2021</risdate><volume>99</volume><spage>107998</spage><epage>107998</epage><pages>107998-107998</pages><artnum>107998</artnum><issn>1567-5769</issn><issn>1878-1705</issn><eissn>1878-1705</eissn><abstract>•A sound rationale for use of IgM-enriched immunoglobulin in severe COVID-19 exists.•CT scores improved in 9/15 patients with severe COVID-19 after IgM-enriched immunoglobulin.•Clinical trials on use of IgM-enriched immunoglobulin in severe COVID-19 are warranted.
The healthcare system in Iran, like most around the world, is managing thousands of patients hospitalised with COVID-19. In Iran, in-hospital mortality is in the region of 25%, rising to 50–60% in patients admitted to intensive care. Hyperinflammation, characterised by cytokine storm, appears to be a hallmark of severe COVID-19 and to date only the anti-inflammatory drug dexamethasone has been shown to reduce mortality in those hospitalised with the disease.
There is a sound scientific rationale behind the use of IgM-enriched immunoglobulin in the management of patients with severe COVID-19. It has been used successfully in the management of hyperinflammation in patients with sepsis and has led to improved radiographic scores in patients with severe cases of severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Recently the successful treatment of a patient with COVID-19 with IgM-enriched immunoglobulin was reported. Here we report the outcome of a further 15 patients hospitalised with COVID-19 treated with IgM-enriched immunoglobulin. Improvements in computed tomography (CT) score were observed in nine patients, indicating that further clinical studies into the use of IgM-enriched immunoglobulin in the treatment of severe COVID-19 are warranted.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34315117</pmid><doi>10.1016/j.intimp.2021.107998</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2021-10, Vol.99, p.107998-107998, Article 107998 |
| issn | 1567-5769 1878-1705 1878-1705 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8299233 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-inflammatory agents Computed tomography Coronaviruses COVID-19 COVID-19 - therapy Cytokine storm Cytokines Dexamethasone Enrichment Health services Humans Hyperinflammation IgM-enriched immunoglobulin Immunoglobulin M Immunoglobulin M - therapeutic use Immunoglobulins Inflammation Intravenous immunoglobulin (IVIG) Iran Lung - pathology Mortality Patients SARS-CoV-2 Sepsis Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases |
| title | IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A06%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IgM-enriched%20immunoglobulin%20in%20COVID-19:%20Case%20series%20of%2015%20severely%20ill%20SARS-CoV-2-infected%20patients&rft.jtitle=International%20immunopharmacology&rft.au=Tabarsi,%20Payam&rft.date=2021-10-01&rft.volume=99&rft.spage=107998&rft.epage=107998&rft.pages=107998-107998&rft.artnum=107998&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.107998&rft_dat=%3Cproquest_pubme%3E2579781059%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579781059&rft_id=info:pmid/34315117&rft_els_id=S1567576921006342&rfr_iscdi=true |